NCT06209359View on ClinicalTrials.gov

Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2028

Conditions
Heart FailureDiuretic Resistance
Interventions
DRUG

Ammonium Chloride

Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.

DRUG

Placebo

Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.

Trial Locations (1)

06510

RECRUITING

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER